Summary
The purpose of this study was to compare the growth-inhibitory effect of cisplatin–paclitaxel with that obtained with a cisplatin–docetaxel combination and to assess the type of interaction. Concomitant use of taxanes and cisplatin was studied in seven human ovarian carcinoma cell lines, using the 96-well plate clonogenic assay. Chemosensitivity was expressed in terms of IC50 values, the drug concentration causing 50% inhibition of clonogenic survival. The type of interaction was studied using the area under the survival curve ratios (AUC ratios) obtained by numerical integration. Comparison of the AUC ratio and the surviving fraction (SF) value after taxane alone was made using Student’s t-test. The influence of the drug concentration was tested by one-way analysis of variance (Anova). A supra-additive or additive effect was seen when seven ovarian carcinoma cell lines were exposed to paclitaxel or docetaxel concomitantly with cisplatin. A supra-additive effect was found in four cell lines (UT-OC-3, UT-OC-4, UT-OC-5 and SK-OV-3) after simultaneous use of cisplatin with all docetaxel concentrations tested, and in two cell lines (UT-OC-4 and SK-OV-3) when cisplatin was used concomitantly with paclitaxel. A more pronounced supra-additive effect was seen with the combination of cisplatin and docetaxel. The degree of supra-additivity was dose dependent, with increasing synergy after a higher taxane dose. The data obtained in this study suggest that a supra-additive or additive effect can be achieved in ovarian carcinoma with the concomitant use of cisplatin and a taxane.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Advanced Ovarian Cancer Trialists Group (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884–893.
Arbuck, S. G., Canetta, R. & Onetto, N. (1993). Current dosage and scheduling issues in the development of paclitaxel (TAXOL). Semin Oncol 4: (suppl. 3)31–39.
Burris, H. A., Fields, S. & Peacock, N. (1995). Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 22: 35–40.
Chou, T. C., Otter, G. M. & Sirotnak, F. M. (1996). Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37: 222–228.
Citardi, M. J., Rowinsky, E. K., Schaefer, K. L. & Donehower, R. C. (1990). Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. Proc Am Assoc Cancer Res 34: 2431–2431.
Diaz, J. F., Menendez, M. & Andreau, J. M. (1993). Assembly of purified GDP-tubulin into microtubules induced by RP 56976 and paclitaxel: reversibility, ligand stoichiometry and competition. Biochemistry 32: 2747–2755.
Engblom, P., Rantanen, V., Kulmala, J. & Grènman, S. (1996). Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res 16: 1743–1748.
Engblom, P., Rantanen, V., Kulmala, J., Heiskanen, J. & Grenman, S. (1997). Taxane sensitivity of ovarian carcinoma in vitro. Anticancer Res 17: 2475–2480.
Fogh, J., Wright, W. C. & Loveless, J. D. (1977). Absence of Hela cell contamination on 169 cell lines derived from human tumours. J Natl Cancer Inst 58: 209–214.
Georgiadis, M. S., Russell, E. & Johnson, B. E. (1994). Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Proc Int Assoc Study Lung Cancer 11: 95–95.
Grènman, R., Burk, D., Virolainen, E., Buick, R. N., Church, J., Schwartz, D. R. & Carey, T. E. (1989). Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131–136.
Gueritte-Voegelein, F., Guenard, D., Lavelle, F., Le Goff, M. T., Mangatal, L. & Potier, P. (1991). Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992–998.
Gullo, J. J., Litterst, A. R., McGuire, W. P., Sikic, B., Hoth, J. & Wooley, P. A. (1980). Pharmacokinetics and protein-binding of cis-dichlorodiamineplatinum (11) administered as a one hour or as a twenty-four hour infusion. Cancer Chemother Pharmacol 5: 21–26.
Hill, B. T., Whelan, R. D. H., Shellard, S. A., McClean, S. & Hosking, L. K. (1994). Differential cytotoxic effects of docetaxel in a range of mammalian tumour cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169–182.
Hino, M., Kobayashi, K., Hayashihara, K., Aoyama, A., Shibuya, M. & Kudo, S. (1995). In vitro combination effect of docetaxel (RP 56976) with vinca alkaloids on cancer cell line. Proc Am Assoc Cancer Res 36: 2995–2995.
Huizing, M. T., Keung, A. C. F. & Rosing, H. (1993). Pharmacokinetics of paclitaxel and metabolites in a randomised comparative study in platinum-pre-treated ovarian cancer patients. J Clin Oncol 11: 2127–2135.
Jekunen, A., Christen, R., Shalinsky, D. & Howell, S. B. (1994). Synergistic interaction between cisplatin and taxol in human ovarian carcinoma in vitro. Br J Cancer 69: 299–306.
Kaye, S. B., Piccart, M., Aapro, M. & Kavanagh, J. J. (1995). Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur J Cancer 31A: 14–17.
Kelland, L. R. & Abel, G. (1992). Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444–450.
Kiyozuka, Y., Nishimura, H., Nakashima, A., Imamura, K., Ota, S., Yakushiji, O. M., Imai, S. & Morimatsu, M. (1995). In vitro cytotoxicity on ovarian cancer of low-dose continuous exposure to microtubule inhibitors (paclitaxel/taxotere) combined with cisplatin. Oncol Rep 2: 517–523.
Koechli, O., Sevin, B-U, Perras, J., Chao Chou, T., Angioli, R., Steren, A., Untch, M. & Averette, H. E. (1993). Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay. Breast Cancer Res Treatment 28: 21–27.
Lavelle, F., Bissery, M-C, Combeau, C., Riou, J. F., Vrignaud, P. & Andrè, S. (1995). Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22: 3–16.
Lopes, N. M., Adams, E. G. & Pitts, T. W. (1993). Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235–242.
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. & Davidson, M. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6.
Parker, R., Lee, K. B. & Dabholkar, M. (1993). Influence of taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 34: 2122–2122.
Piccart, M. J., Bertelsen, K. & Stuart, G. (1997). Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOVOCA, NCI-C and Scottish Intergroup experience. Proc Am Soc Clin Oncol 16: 352–352.
Rantanen, V., Grènman, S., Kulmala, J. & Grènman, R. (1994). Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482–486.
Riou, J. F., Naudin, A. & Lavelle, F. (1992). Effects of taxotere on murine and human tumour cell lines. Biochem Biophys Res Commun 187: 164–170.
Riou, J. F., Petingenet, O., Combeau, C. & Lavelle, F. (1994). Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 35: 384–384.
Rowinsky, E. K., Donehower, R. C. & Jones, R. J. (1988). Microtubule changes and cytotoxicity in leukaemia cell lines treated with Taxol. Cancer Res 48: 4093–4100.
Saunders, D. E., Christensen, C. & LoRusso, P. M. (1992). Inhibition of ovarian carcinoma cells by taxol combined with vitamin D and adriamycin. Proc Am Assoc Cancer Res 33: 2641
Schiff, P. B. & Gubits, R., Kashimawo (1995). Paclitaxel with ionising radiation. In Paclitaxel in Cancer Treatment, McGuire WP, Rowinsky EK, (eds), pp. 81–90, Marcel Dekker: New York
Thigpen, J. T., Blessing, J. A., Vance, R. B. & Lambuth, B. W. (1989). Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 16: 58–65.
Thilly, W. G., Deluca, J. G., Furth, E. E., Hoppe, H., Kaden, D. A., Krolenski, J. J., Liber, H. L., Skopek, T. R., Laslapikoff, S. A., Tizard, R. J. & Penman, B. W. (1980). Gene-locus mutation assays in diploid human lymphoblast lines. In Chemical mutagens, de Serpes FJ, Hollander A (eds), pp. 331–364. Plenum: New York
Untch, M., Sevin, B-U, Perras, J. P., Angioli, D. R., Untch, A., Hightower, R. D., Koechli, O. & Averette, H. E. (1994). Evaluation of paclitaxel (Taxol), cisplatin and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP-cell viability assay. Gynecol Oncol 53: 44–49.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Engblom, P., Rantanen, V., Kulmala, J. et al. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br J Cancer 79, 286–292 (1999). https://doi.org/10.1038/sj.bjc.6690046
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690046
Keywords
This article is cited by
-
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer
Cancer Chemotherapy and Pharmacology (2016)
-
A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format
Journal of Ovarian Research (2015)
-
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer
Medical Oncology (2010)
-
European experience of docetaxel and cisplatin in advanced gastric cancer
Gastric Cancer (2002)